Magnomics has a team with world-class experience in biotechnology, electronics, and physics, and has won several innovation awards. The company's technology uses microfluidics and a novel magnetoresistive DNA sensing technology to provide a portable and affordable PCR device that requires no training to operate. Magnomics will focus on the veterinary diagnostics market, with a target on bovine mastitis, which causes over €30 billion in annual losses for producers worldwide. The company's product can detect multiple pathogens and will be sold either directly to farmers or to veterinarians, with strategic partnerships being negotiated with large pharma/dairy players to ensure market access. Competitors in the market include AAD, DeLaval, and PortaCheck, but Magnomics aims to bring molecular solutions to the farm in a convenient and affordable product.